LCTX Lineage Bio: Multiplikator Forward P/S

Lineage Corp (LCTX) - logo korporat

Does the laboratory operational format of Lineage Cell Therapeutics (LCTX) impact the environment? The answer lies in the creation of precise cryogenic biomaterial delivery networks that support profitability. This forward price-to-sales chart confirms this success, with the metric standing at 19.00. This price action underscores the company's commitment to restoring spinal cord tissue and vision through regenerative medicine.

lineagecell.com - Prakiraan rega marang pendapatan LCTX (periode 04.07.2022 - 13.11.2026)

Rincian metrik komprehensif lan analitis Lineage Corp (LCTX)

- rega saiki lan proyeksi nilai saham:
Rega saham Lineage Cell Therapeutics, Inc.|LCTX - Rata-rata rega prakiraan
- data kapitalisasi saham perusahaan:
Kapitalisasi pasar Lineage Corp|LCTX - Nilai Perusahaan
- statistik nilai buku emiten:
Nilai Buku saben Saham Lineage Cell Therapeutics|LCTX - Nilai Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku lineagecell.com|LCTX - Aset Perusahaan
- indikator beban kredit lan likuiditas emiten:
Rasio Total Utang marang Ekuitas Lineage Cell Therapeutics|LCTX - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Lineage Cell Therapeutics|LCTX - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Lineage Corp|LCTX - Utang jangka dawa|Utang jangka cendhak perusahaan Lineage Cell Therapeutics|Likuiditas cepet lineagecell.com
- rincian asil keuangan lan kelipatan valuasi:
LCTX - Bathi resik perusahaan|Bathi mangsa ngarep Lineage Cell Therapeutics|LCTX - Nilai perusahaan marang bathi resik|Prakiraan rega marang bathi Lineage Bio|LCTX - Rasio nilai perusahaan marang wutah bathi|Pangali EV/EBITDA Lineage Corp|LCTX - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Lineage Cell Therapeutics|LCTX - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan lineagecell.com|LCTX - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Lineage Cell Therapeutics
- data pendapatan lan penerimaan dodolan:
LCTX - Pendapatan lan volume dodolan|Prakiraan pendapatan perusahaan Lineage Cell Therapeutics, Inc.|LCTX - Rasio rega marang dodolan|Multiplikator Forward P/S Lineage Corp
Analisis kabeh metrik perusahaan:Lineage Cell Therapeutics, Inc. LCTX
Produk sing diprodhuksi Lineage Corp

To find a balance between cost and business quality, use the forward P/S ratio, which correlates current market capitalization with updated revenue expectations, reflecting the dynamics of market risks. In the case of Lineage Cell Therapeutics (LCTX), the company's projected P/S demonstrates how the market values the commercialization potential of cell therapy for macular dystrophy, accounting for the operational costs priced in and the upcoming scaling of clinical trials.

Analisis pesaing

Multiplikator Forward P/S MESO (Mesoblast)|Surrozen Inc (SRZN) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Cryo-Cell International Inc - Multiplikator Forward P/S|FBLG - Multiplikator Forward P/S|LGVN: Multiplikator Forward P/S|Prakiraan rega marang pendapatan BioRestorative Therapies, Inc. BRTX|CELZ (Creative Medical Technology Holdings, Inc.) - Multiplikator Forward P/S